Sign In
Buy ITCI
$131.87
+0 (+0%)
At Close: Jul 01, 2025
Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast
08:00am, Wednesday, 26'th Apr 2023
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ne
Intra-Cellular's (ITCI) Caplyta Aids Sales, Overreliance a Woe
12:56pm, Friday, 21'st Apr 2023
Intra-Cellular (ITCI) is witnessing growth aided by its sole-marketed drug, Caplyta. However, the lack of other promising candidates in the pipeline is concerning.
Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?
01:04pm, Friday, 31'st Mar 2023
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up
04:27pm, Wednesday, 29'th Mar 2023 Zacks Investment Research
Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.
Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback
03:24pm, Wednesday, 29'th Mar 2023 Zacks Investment Research
Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.
Analyst Ratings for Intra-Cellular Therapies
03:00pm, Wednesday, 29'th Mar 2023 Benzinga
Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ:ITCI) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
6
Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up
01:46pm, Wednesday, 29'th Mar 2023
Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.
Airbnb To Rally Around 59%? Here Are 10 Other Analyst Forecasts For Wednesday
12:18pm, Wednesday, 29'th Mar 2023 Benzinga
Keybanc raised the price target for Intuit Inc. (NASDAQ: INTU) from $450 to $475. Keybanc analyst Josh Beck maintained an Overweight rating. Intuit shares fell 1.8% to close at $419.33 on Tuesday.
T
Intra-Cellular (ITCI) Surges 16.4%: Is This an Indication of Further Gains?
09:36am, Wednesday, 29'th Mar 2023 Zacks Investment Research
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre
Intra-Cellular (ITCI) Surges 16.4%: Is This an Indication of Further Gains?
06:54am, Wednesday, 29'th Mar 2023
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre
Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
05:04pm, Tuesday, 28'th Mar 2023 Benzinga
Gainers
Biomea Fusion, Inc. (NASDAQ: BMEA) surged 56.8% to $24.20 after the company announced data from the initial cohorts of the ongoing Phase II study of BMF-219 in patients with type 2 diabetes;
Why Intra-Cellular Therapies Climbed Tuesday
04:27pm, Tuesday, 28'th Mar 2023 The Motley Fool
The company's depression drug, Caplyta (lumateperone), did well in a phase 3 trial against two types of depression.
Why Intra-Cellular Therapies Climbed Tuesday
12:27pm, Tuesday, 28'th Mar 2023
Caplyta, the company's lead drug, was responsible for most of the company's revenue in 2022. The potential addition of major depressive disorder to the indications Caplyta treats would significantly i
Lumateperone 42mg was statistically significant on the primary endpoint of symptom reduction on the Montgomery Asberg Depression Rating Scale (MADRS) for each patient population including:
Intra-Cellular's Big Depression Drug Market Just Got Bigger — And Shares Catapulted
10:04am, Tuesday, 28'th Mar 2023
Intra-Cellular said Tuesday its depression treatment succeeded in a key study, and ITCI stock broke definitively above its 200-day line. The post Intra-Cellular's Big Depression Drug Market Just Got B
